AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21303190
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (twice weekly for 3 weeks, total six sessions)
Trial: 21303190
Drug: Observation (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (routine care with weekly visits)
Trial: 11942472
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in plasma 8-iso-prostaglandin F2alpha (SD = 8.88 ng/L)
Trial: 11942472
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in apolipoprotein B (SD = 0.27 g/L)
Trial: 2679288
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and fluorouracil (M-F) followed by leucovorin in Protocol B-13
Trial: 2679288
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg twice daily) in Protocol B-14
Trial: 785426
Drug: Aerosol vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol vaccine
Trial: 785426
Drug: Whole-virion vaccine
RxNorm normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virion vaccine
Trial: 785426
Drug: Tween-ether ‘split’
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tween-ether ‘split’ vaccine
Trial: 785426
Drug: Aerosol vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol vaccine (field trial)
Trial: 785426
Drug: Whole-virion vaccine
RxNorm normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virion vaccine (field trial)
Trial: 29411724
Drug: LACB-7 (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACB-7 (7-day quadruple therapy)
Trial: 29411724
Drug: LACB-14 (14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACB-14 (14-day quadruple therapy)
Trial: 20846715
Drug: Thalidomide 200mg
RxNorm normalized name: THALIDOMIDE 200MG CAP
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 200mg daily (escalated to 400mg)
Trial: 20846715
Drug: Tamoxifen 20mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20mg orally twice daily
Trial: 31959397
Drug: Implant-supported cantilever
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported cantilever fixed partial dentures (ICFPDs)
Trial: 31959397
Drug: Implant-supported conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported conventional fixed partial dentures (IFF)
Trial: 27492975
Drug: Orafti® Inulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orafti® Inulin (3 x 4g daily for 4 weeks)
Trial: 11566619
Drug: Onercept 50
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50 mg IV
Trial: 11566619
Drug: Onercept 150
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 150 mg IV
Trial: 11566619
Drug: Onercept 50
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50 mg SC (single injection)
Trial: 11566619
Drug: Onercept 50
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50 mg SC (six repeated injections)
Trial: 11566619
Drug: Onercept (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept (various doses)
Trial: 9470156
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVGG) at a dosage of 0.5 g/kg (range 0.25 to 0.73 g/kg) administered after 10.4 +/- 6.6 days of prednisone therapy
Trial: 31722536
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy alone
Trial: 30204730
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment guided by visual acuity stabilization criteria (Group I)
Trial: 30204730
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment guided by disease activity (Group II)
Trial: 30204730
Drug: Verteporfin photodynamic
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin photodynamic therapy (Group III)
Trial: 30204730
Drug: Ranibizumab injections
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab injections (Groups I/II)
Trial: 28010989
Drug: Mesh augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesh augmentation
Trial: 28010989
Drug: Graft augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graft augmentation
Trial: 25517761
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with 3 × 5 min occlusion
Trial: 21192150
Drug: Citalopram or
RxNorm normalized name: citalopram Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram or Fluoxetine (dose increase at week 6)
Trial: 21192150
Drug: SSRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI plus cognitive behavior therapy
Trial: 21192150
Drug: Venlafaxine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine plus cognitive behavior therapy
Trial: 17123235
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg (GRA1) + 8 mg dexamethasone
Trial: 17123235
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg (GRA3) + 8 mg dexamethasone
Trial: 17123235
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg (OND8) + 8 mg dexamethasone
Trial: 9482177
Drug: Ebselen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen (150 mg, twice a day for 2 weeks)
Trial: 8059693
Drug: Volume loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume loading (mean 400 ml saline solution)
Trial: 3143264
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and glyburide
Trial: 29121326
Drug: Increased FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased FSH dose (225/450 IU/day)
Trial: 29121326
Drug: Standard FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard FSH dose (150 IU/day)
Trial: 22079215
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (CBT)
Trial: 23669884
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control treatment (MoodGYM)
Trial: 15273918
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy in hypogonadal patients
Trial: 15273918
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy of calcium and vitamin D
Trial: 6752712
Drug: Oxprenolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (40 mg twice daily)
Trial: 29089066
Drug: Lotilaner (Credelio™)
RxNorm normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner (Credelio™) at a dose of 20 mg/kg, administered orally 30 minutes after feeding.
Trial: 21835280
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg dalcetrapib daily for 24 months
Trial: 21835280
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 24 months
Trial: 16703780
Drug: 4.5%/8.5% benzoyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral doxycycline
Trial: 16703780
Drug: 4.5%/8.5% benzoyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral minocycline
Trial: 14654718
Drug: GH 0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 0.23 mg/kg/week (group A)
Trial: 14654718
Drug: GH 0.46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 0.46 mg/kg/week (group B)
Trial: 14654718
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (both groups)
Trial: 9671870
Drug: Levofloxacin 250
RxNorm normalized name: levofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 250 mg once daily
Trial: 1316058
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg once daily
Trial: 7836549
Drug: Tacrine (Cognex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (Cognex, THA) administered after an 8-hour overnight fast
Trial: 7836549
Drug: Tacrine (Cognex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (Cognex, THA) administered 1 hour before a standard breakfast
Trial: 7836549
Drug: Tacrine (Cognex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (Cognex, THA) administered 15 minutes after beginning a standard breakfast
Trial: 7836549
Drug: Tacrine (Cognex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (Cognex, THA) administered 2 hours after completion of a standard breakfast
Trial: 3046277
Drug: Sotalol, 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol, 160 mg twice daily
Trial: 3046277
Drug: Atenolol, 50
RxNorm normalized name: Atenolol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 50 mg twice daily
Trial: 3046277
Drug: Intravenous sotalol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sotalol, 100 mg
Trial: 3046277
Drug: Intravenous atenolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous atenolol, 10 mg
Trial: 23650294
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate 0.5% gel
Trial: 21068676
Drug: Creatine (PEG-creatine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (PEG-creatine, 5 g·d)
Trial: 21068676
Drug: Placebo (maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin powder, 5 g·d)
Trial: 12675866
Drug: Dual blockade
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual blockade of the renin-angiotensin system (RAS) with irbesartan 300 mg (once daily) and enalapril 40 mg (once daily)
Trial: 12675866
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors + placebo
Trial: 10963287
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) plus medical treatment
Trial: 9151611
Drug: One-stage IMZ
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage IMZ implant placement
Trial: 9151611
Drug: Two-stage IMZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage IMZ implant placement
Trial: 8403954
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics (tobramycin, polymyxin E, amphotericin B, vancomycin)
Trial: 8403954
Drug: Placebo (suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (suspension of fluid and paste without antibiotics)
Trial: 2885854
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg per day)
Trial: 2885854
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg per day)
Trial: 18211927
Drug: Deep Sclerectomy
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Sclerectomy with Collagen Implant (DSCI)
Trial: 8626359
Drug: Nefazodone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (mean dose at endpoint = 379 mg/day)
Trial: 1336527
Drug: Captopril at
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril at 25 mg twice a day
Trial: 1336527
Drug: Atenolol at
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol at 50 mg once a day
Trial: 30972581
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or group cognitive-behavioral therapy for 14 weeks
Trial: 18698012
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin (162 mg)
Trial: 18698012
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl salicylate (5 g of 30% preparation)
Trial: 16385104
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment strategies for migraine
Trial: 16385104
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment strategies for migraine
Trial: 12450883
Drug: High-protein, high-methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein, high-methionine diet (HP: 22% of total energy, 2.7 g methionine/d; n = 25)
Trial: 12450883
Drug: Low-protein, low-methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein, low-methionine diet (LP: 12% of total energy, 1.4 g methionine/d; n = 25)
Trial: 10369491
Drug: Iron (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (14 mg/d) and 60 mg/d vitamin C (Group A)
Trial: 10369491
Drug: Iron (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (14 mg/d) and 260 mg/d vitamin C (Group B)
Trial: 7575897
Drug: Infusions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions of 250 ml 10% HES 200/0.5
Trial: 7575897
Drug: Infusions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions of 500 ml 10% HES 200/0.5
Trial: 7575897
Drug: Saline infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusions (previous study)
Trial: 786694
Drug: Salmefamol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmefamol 1 mg
Trial: 786694
Drug: Salmefamol 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmefamol 2 mg
Trial: 28068987
Drug: Acetyl-DL-leucine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-DL-leucine (up to 5 g per day)
Trial: 24083628
Drug: Facial massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facial massage therapy
Trial: 19488741
Drug: Nicotine (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (14 mg for smokers, 7 mg for nonsmokers)
Trial: 12527540
Drug: Cognitive/Behavioral Therapy-Alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive/Behavioral Therapy-Alone (C/B-Alone)
Trial: 9345325
Drug: HFX/PE (Hyperfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX/PE (Hyperfractionated radiation therapy with concurrent chemotherapy)
Trial: 9345325
Drug: HFX (Hyperfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX (Hyperfractionated radiation therapy alone)
Trial: 3954817
Drug: Drugs from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs from 7 psychopharmacological classes
Trial: 31234234
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist intervention via home medication management review (HMMR)
Trial: 27020070
Drug: Oxytocin treatment
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin treatment (placebo)
Trial: 27020070
Drug: Serotonin treatment
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin treatment (placebo)
Trial: 8620707
Drug: No rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rehabilitation therapy (Control group)
Trial: 2011430
Drug: Methylphenidate 5
RxNorm normalized name: dexmethylphenidate 5.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 5 mg twice a day
Trial: 2011430
Drug: Methylphenidate 10
RxNorm normalized name: dexmethylphenidate 10.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 10 mg twice a day
Trial: 2011430
Drug: Methylphenidate 15
RxNorm normalized name: METHYLPHENIDATE 15MG/9HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 15 mg twice a day
Trial: 2011430
Drug: Moderate to
RxNorm normalized name: GenTeal Moderate to Severe Ophthalmic Gel Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate to high dose of methylphenidate
Trial: 30053298
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate supplementation to maintain venous bicarbonate levels at 24-26 mEq/L along with standard care as per KDIGO 2012 guidelines
Trial: 30053298
Drug: Intervention arm
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention arm with oral sodium bicarbonate supplementation
Trial: 8610232
Drug: Vinorelbine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (single agent)
Trial: 8610232
Drug: Vindesine/Cisplatin (combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine/Cisplatin (combination)
Trial: 8610232
Drug: Vinorelbine/Cisplatin (combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine/Cisplatin (combination)
Trial: 7044797
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg t.i.d.
Trial: 7044797
Drug: Benoxaprofen 600
RxNorm normalized name: fenoprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxaprofen 600 mg once daily
Trial: 23983157
Drug: Nontraditional retention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontraditional retention strategy - school administration assistance
Trial: 15226663
Drug: e-AGV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-AGV group (AGV implant surgery using pericardial membrane)
Trial: 15226663
Drug: AGV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGV group (AGV implant surgery without surface area extension)
Trial: 12190806
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) 2 ml i.v.
Trial: 12190806
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 30 s
Trial: 12190806
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 60 s
Trial: 12190806
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg in 2 ml NS with venous occlusion (VO) for 120 s
Trial: 12190806
Drug: Ketorolac 15
RxNorm normalized name: ketorolac 15.75 mg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 15 mg in 2 ml NS with propofol injection after 60 s
Trial: 12190806
Drug: Ketorolac 30
RxNorm normalized name: ketorolac 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg in 2 ml NS with propofol injection after 60 s
Trial: 9694611
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/day for 2 years (postmenopausal)
Trial: 9694611
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy (TAM + MMC + CPA)
Trial: 2527044
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10.0 mg/d) in combination with HCTZ (50 mg/d)
Trial: 2527044
Drug: HCTZ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ (50 mg/d) with placebo
Trial: 31539295
Drug: Single-agent panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-agent panitumumab
Trial: 28536206
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg dextrose gel
Trial: 17999976
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of 600 mg linezolid
Trial: 17999976
Drug: Twice-daily administration
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily administration of linezolid (extrapolated)